Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: J Pathol. 2010 Sep;222(1):110–116. doi: 10.1002/path.2739

Table 4.

Variables in common between the tubal p53 signature and pelvic serous cancer

  1. Initiates in the distal fallopian tube (fimbria). 8, 12

  2. Occurs in the setting of cellular DNA damage (γ-H2AX). 12

  3. Targets the tubal secretory cell (HMFG2/BCL2/PAX8(+), p73/LHS28(−)).11, 12

  4. Strong nuclear accumulation of p53. 11, 12

  5. PAX2 down-regulation (current study).

  6. Sequence confirmed ovarian cancer-associated p53 mutations (current study). 8, 12

  7. Documented continuity between the p53 signature and intraepithelial carcinoma with shared p53 mutations and loss of PAX2 expression (current study).

  8. Existence of intermediate forms (proliferating p53 signatures) with features of both p53 signature and STIC. 12, 13